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1  | INTRODUCTION
Hemophilia A is an inherited bleeding disorder caused by the plasma 
deficiency of coagulation factor VIII (FVIII). The clinical picture of 
patients with hemophilia A is characterized by bleeding episodes 
that occur spontaneously or at the time of trauma.1 The earliest 
and most serious bleeding in neonates is intracranial hemorrhage, 
which occurs in 1%- 4% of severely affected cases.2 With age, the 
hemorrhagic diathesis affects soft tissue, joints, and muscles, lead-
ing to arthropathy, deformity and disability.3,4 To prevent these 
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Abstract
The development of FVIII inhibitory antibodies is currently the most challenging 
complication of treatment, affecting ~30% of severe hemophilia A patients. These 
inhibitors inactivate FVIII, rendering the treatment ineffective, causing disability and 
increasing morbidity and mortality. Inhibitor development results from a complex 
multicausal immune response involving both genetic and environmental risk factors. 
One of the most important modifiable risk factors is the source of FVIII products, eg, 
plasma- derived or recombinant FVIII. Other environmental risk factors, such as age 
at first treatment, regimen, and intensity of treatment, could contribute to inhibitor 
development. Severe bleeds, surgery, concomitant infections, or vaccinations may all 
be events initiating danger signaling resulting in an immune reaction towards admin-
istered FVIII. All in all, the etiology of inhibitor development still remains unclear. The 
risk factors have been stratified into genetic and environmental, but there are no 
definitive data to determine the impact of each of them.
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Essentials
• Treatment complications in hemophilia A: inhibitors development.
• Type of FVIII products: the latest updates on plasma-derived or recombinant FVIII immunogenicity.
• SIPPET study, the first randomized study contrasting plasma-derived FVIII and recombinant FVIII products.
• The impact of other environmental risk factors in the etiology of inhibitor formation, such as age at first treatment, regimen and in-
tensity of treatment, severe bleeds, surgery, concomitant infections, or vaccinations.
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complications, patients are treated by means of regular infusions of 
plasma- derived or recombinant FVIII concentrates. There have been 
many advances to optimize and ensure the safety and effectiveness 
of FVIII concentrates during the last 30 years, after the successful 
control of complications caused by such bloodborne pathogens as 
HIV and hepatitis C.5 However, these improvements are darkened by 
a serious complication, ie, inhibitor development, recorded in more 
than 30% of severely affected patients within their initial 20- 30 
exposure days (EDs) to administered FVIII. The risk of inhibitor de-
velopment is greatest in previously untreated patients (PUPs) and is 
strongly associated with the severity of the disease. FVIII inhibitors 
consist of a polyclonal population of antibodies, mainly IgG4, IgG1, 
and IgG2 subclasses that target multiple antigenic sites within the 
A2, A3, and C2 domains of the FVIII protein.6,7 The appearance of 
these alloantibodies neutralizes the hemostatic effect of FVIII con-
centrates, rendering the management of bleeding episodes difficult.
The immunology of inhibitor development is complex and not 
completely understood. The etiology of inhibitor development is the 
result of a multistep process that involves a cascade of interactions 
between genetic and environmental determinants. Several predis-
posing genetic risk factors (ie, inhibitor family history, ethnicity, F8 
gene mutations, and variants in a number of genes involved in the 
immune response) have been reported to have an effect on inhib-
itor development. The type of F8 gene mutation has been clearly 
associated with inhibitor risk, and null mutations are associated with 
the highest risk in patients with severe hemophilia A.8 A large num-
ber of environmental factors may contribute to the risk of inhibitor, 
such as the type of FVIII product, age at first treatment, intensity of 
treatment, and danger signals such as surgery, severe bleeds, vac-
cinations, and infections.9–11 Identifying the environmental factors 
implicated in inhibitor development might permit anticipation of its 
onset and possibly lead to the potential to intervene, and thereby 
change patient treatment and improve outcomes.
This article gives an overview on the debated role of the source 
of FVIII concentrate and on the impact of other environmental risk 
factors in the etiology of inhibitors. Our review includes recent stud-
ies presented during the International Society on Thrombosis and 
Haemostasis (ISTH) 2017 meeting on the (i) timing and severity of 
inhibitor development, and (ii) the impact of danger signals.
2  | HISTORICAL OVERVIEW
A circulating inhibitor, called “anticoagulant,” was identified for the 
first time in the 1940s in a patient affected with hemophilia.12,13 
Three hours after the blood transfusions, the patient began to bleed 
continuously and the coagulation time remained markedly pro-
longed.12,13 Later, this inhibitor was shown to be a γ- globulin and to 
appear only after repeated transfusions of whole blood.14,15 Thus, 
the anticoagulant was suggested to be the result of an immuniza-
tion of patients to the deficient factor. Only in the late 1960s to 
early 1970s was it recognized that circulating anticoagulants were 
antibodies which developed in patients with hemophilia in response 
to replacement therapy.16 At that time, determinants of the occur-
rence of circulating anticoagulants in hemophilia were unknown. In 
addition, it was not clearly established whether the development of 
circulating anticoagulants was influenced by the quantity, type, or 
frequency of replacement therapy.17 During these years hemophilic 
patients were receiving much more treatment than in previous early 
years due to the development of technologies able to separate FVIII 
from large pools of donor plasma that resulted in the availability of 
freeze- dried, lyophilized FVIII concentrates. However, there was no 
evidence that one type of FVIII concentrate was more prone than 
others to produce inhibitor. In the 1980s and 1990s, there was a con-
siderable amount of controversy and debate on the risk of inhibitor 
formation associated with the type of plasma- derived FVIII products 
with different purity. In those early days, inhibitor incidence was 
low, corresponding to 6%- 7% in patients treated exclusively with 
plasma cryoprecipitate and remained relatively low, around 9%- 10%, 
in patients treated with intermediate- purity FVIII concentrates.18–22 
The introduction of viral inactivation steps to produce new plasma- 
derived products improved the safety by minimizing the potential 
of bloodborne pathogen transmission. However, these additional 
steps in the manufacturing process probably made plasma- derived 
products more immunogenic with a higher risk of inhibitors which 
was estimated up to 20%- 25%.23–27 For instance, the introduction 
of a pasteurized version of a previously dry- heated FVIII concen-
trate in order to obtain a higher purity concentrate (CPS- P) was as-
sociated with an outbreak of inhibitors in multi- transfused patients 
in the Netherlands and Belgium.28,29 The heat- treated product was 
associated with a rate of new inhibitor development of 4.4/1000 
patient- years, which increased to 20.1/1000 patient- years with the 
new pasteurized product.28,29 The authors concluded that the com-
plex process of FVIII purification and viral inactivation, such as pas-
teurization and solvent- detergent treatment, may have altered the 
molecule, provoking inhibitor development.28,29
3  | IMPACT OF RECOMBINANT 
PRODUCTS: FROM OBSERVATIONAL TO 
RANDOMIZED STUDIES
The subsequent novel availability of recombinant FVIII concentrates 
in the early 1990s has added another variable to the issue of inhibi-
tor risk. These preparations, derived from nonhuman mammalian cell 
lines, are associated with changes in the posttranslational process-
ing or tertiary structure of FVIII that may lead to the formation of 
neoantigens and make these preparations more immunogenic than 
plasma- derived FVIII products.
The safety and efficacy of recombinant FVIII products were pri-
marily tested in previously treated patients (PTPs, ie, patients having 
at least 150 EDs) for bleeding episodes, as requested by the guide-
lines for marketing authorization. These studies also evaluated the 
risk of inhibitor formation and indicated that in PTPs recombinant 
FVIII products were no more immunogenic than plasma- derived 
FVIII.30,31 However, PTPs are at a much lower risk of inhibitor 
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development than PUPs.30–33 In the first few studies designed to 
evaluate safety, efficacy, and inhibitor risk of recombinant FVIII 
concentrates in PUPs, all the investigated products were well tol-
erated and not associated with significant adverse events, and the 
responses to treatment were excellent. However, the cumulative in-
cidence of inhibitors was high, varying between 25% and 30%.30–33
In the next few years, some evidence emerged that different 
FVIII preparations had different degrees of immunogenicity, and a 
number of reports showed a lower rate of inhibitors in PUPs treated 
with plasma- derived products than with recombinant products. The 
cumulative risk of inhibitor development ranged from 20% to 33% in 
PUPs treated with various plasma- derived products.34,35 In contrast, 
patients treated with a single plasmatic concentrate had a cumula-
tive incidence ranging from 10% to 12.4%,19,23 whereas inhibitor de-
velopment in patients treated with a single recombinant product was 
much higher, ranging from 27.6% to 36%.32,36–39
Strong clinical support to the view that plasmatic FVIII con-
centrates are less immunogenic than recombinant FVIII was pro-
vided in 2003 by a systematic review on the epidemiology of FVIII 
inhibitors.40 In an analysis of 801 PUPs in the frame of 13 obser-
vational studies originally carried out to evaluate the efficacy and 
safety of an array of FVIII products, the risk of inhibitor develop-
ment was more than double in patients treated with recombinant 
FVIII as opposed to plasma- derived products.41 However, two sub-
sequent multicenter observational studies, the CANAL (Concerted 
Action on Neutralizing Antibodies in severe haemophiLia A) study 
(316 PUPs)42 and the larger RODIN (Research Of Determinants of 
INhibitor development) cohort study (574 PUPs)43 showed no dif-
ference in immunogenicity between plasma- derived and recombi-
nant FVIII products. Unexpectedly the RODIN study also reported 
that second- generation full- length recombinant products were as-
sociated with an increased risk of inhibitor as compared with third- 
generation products (adjusted hazard ratio 1.60; 95% CI, 1.08- 2.37). 
Subsequently, this higher immunogenicity observed for second- 
generation full- length recombinant products was confirmed in a co-
hort of patients included in the Rèseau FranceCoag and in the UK 
children registered in the UKHCDO National Haemophilia Database 
(NHD) and most recently in the FranceCoag PUP cohort.44–46 
Two additional studies, the EUHASS study47 and a Canadian co-
hort study,48 who also investigated the higher immunogenicity of 
the second- generation recombinant products, did not confirm the 
RODIN data, but were small or did not inform adjustment for con-
founding. Subsequently, an attempt was made to reconcile these 
contrasting results. Some meta- analysis and systematic reviews, 
based also on data from individual observational studies, reported 
a higher risk of inhibitor development with recombinant FVIII than 
with plasma- derived FVIII, although the difference were attenuated 
after adjustment for confounders.49–51 It must be kept in mind that 
all observational studies may suffer from confounding by indication, 
ie, when the choice of product class was made on the basis of treat-
ers’ perception of inhibitor risk.
To sum up, observational studies, meta- analysis, and system-
atic reviews suggested the existence of a difference between 
plasma- derived and recombinant FVIII products and that plasma- 
derived products determine a lower incidence of inhibitors, but 
due to confounding these results were not conclusive. For instance, 
in a debate article on the question whether the rate of inhibitors 
was higher with recombinant or plasma- derived products, the au-
thor stated that “it is unlikely that in the near future we will have 
sufficient prospective randomized studies to resolve definitively 
the dilemma of inhibitor induction.”52 This statement highlights the 
complexity to carry out a randomized clinical trial but also its need 
in order to obtain final and conclusive results on the major current 
complication of hemophilia therapy.
With this background and gaps of knowledge, the first random-
ized study contrasting plasma- derived and recombinant FVIII prod-
ucts, the Study on Inhibitors in Plasma- Product Exposed Toddlers 
(SIPPET) trial was started in 2010 and published in 2016.53 The study 
included 251 previously untreated hemophilia A boys (<6 years) ran-
domly assigned to receive a VWF- containing plasma- derived FVIII 
product or a recombinant FVIII product and followed for inhibitor 
development for 50 EDs. Patient enrollment took place in 42 cen-
ters from 14 countries in the world. The SIPPET study provided clear 
evidence of a differential immunogenicity risk associated with re-
combinant FVIII products. The cumulative incidence of all inhibitors 
was 26.8% (95% CI, 18.4- 35.2) with plasma- derived FVIII and 44.5% 
(95% CI, 34.7- 54.3) with recombinant FVIII,52 showing that the class 
of recombinant FVIII products was associated with an 87% higher 
incidence of inhibitor than plasma- derived FVIII products.53 These 
data created a debate within the hemophilia treatment community 
on the clinical consequences of the outcome of SIPPET.54 In addi-
tion, a few post hoc analyses of SIPPET provided additional data. 
For instance, the rate of inhibitor incidence was evaluated over time 
every 5 EDs (from 0 to 50 EDs) in hemophilia patients treated with 
different classes of FVIII products.55,56 The highest rates of inhibitor 
occurrence were developed in the first 10 EDs, with a great contrast 
between recombinant and plasma- derived FVIII during the first 5 
EDs: hazard ratio 3.14 (95% CI, 1.01- 9.74) for all inhibitors and 4.19 
(95% CI, 1.18- 14.8) for high- titer inhibitors. For patients treated with 
plasma- derived FVIII, the peak of inhibitor development occurred 
later (6- 10 EDs) and was of shorter duration. These results empha-
size once again the high immunologic vulnerability of patients during 
the earliest exposure to FVIII but also the strongest response to re-
combinant FVIII products.56 Finally, it must be mentioned that most 
recently Calvez et al.46 reported data from a French national cohort 
study concordant with findings from the SIPPET randomized trial, ie, 
a higher risk of inhibitor development in patients treated with recom-
binant than with plasma- derived products (1.64; 95% CI, 0.82- 3.25).
4  | ENVIRONMENTAL RISK FACTORS
4.1 | Age, treatment regimen, and intensity of 
treatment
The possible role played by other environmental risk factors in inhib-
itor development, such as age at first treatment, type of treatment 
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regimen, and intensity of treatment, has been extensively discussed. 
Additional risk factors such as severity of bleeds, surgery, concomi-
tant infections, or vaccinations have also been implicated in the con-
text of concurrent immunological danger signals resulting in immune 
reactions in association with FVIII administration (Figure 1).9–11
The age at which to initiate therapy is a debated matter. In the 
early 2000s, Lorenzo et al. showed that the incidence of inhibitors 
was higher in patients initiating therapy before the age of 6 months 
than for older pediatric patients.34 In keeping with this study, van 
der Bom et al. confirmed the role of first treatment at an early age 
in the development of inhibitors, with a cumulative incidence at 100 
EDs of 34% (95% CI 7%- 61%) in patients starting therapy before 
the age of 6 months and 13% (0%- 27%) in those starting between 
1 and 1.5 years.57 These observations were consistent with subse-
quent findings by Santagostino et al. in patients who had their first 
treatment before the age of 11 months, an effect, however, that 
was attenuated after adjustment for FVIII genetic risk factors.58 
Subsequently, a multivariate analysis, conducted in the frame 
of a French cohort of patients with severe hemophilia, showed a 
threefold difference in inhibitor risk between children treated for 
the first time before 6 months of age compared to those treated 
after 12 months of age.59 Furthermore, the data published in the 
CANAL study demonstrated that the rate of inhibitor was associ-
ated with age at first treatment, diminishing from 41% for patients 
treated within the first months of age to 18% in those treated after 
18 months, but this association largely vanished after adjustment 
for Confounders.42 In a report by Chalmers et al.,60 the exposure to 
FVIII throughout the neonatal period showed no association with a 
higher incidence of inhibitors than in patients treated later during 
the first year of life. Two additional studies published most recently 
found no association between age of therapy initiation and inhibitor 
formation during the first years of life.46,61 To sum up, the data re-
ported in the literature are discordant, in all likelihood owing to the 
observational nature of the studies, and thus fail to support firmly 
the hypothesis that a first replacement therapy at an early age in-
creases the risk of inhibitor formation.
The role of prophylaxis has also been examined as a potential risk 
factor in the development of inhibitors. In the frame of the CANAL 
study, Gouw et al. showed that prophylaxis was associated with a 
decreased inhibitor risk as compared with on- demand treatment,42 
but the subsequent case- control study of the UKHCDO did not con-
firm the protective role of prophylactic regimens.62 In a pilot study 
conducted in 2010, Kurnik et al. analyzed whether a low- dose pro-
phylaxis regimen for the first 20 to 50 EDs did induce tolerance to the 
administered FVIII and minimize inhibitor development63 and found 
that the cumulative inhibitor incidence in the low- dose group was 
strikingly reduced compared with the control group on a standard 
protocol (OR: 0.048, 95% CI, 0.001- 0.372). The authors concluded 
that early beginning of prophylaxis decreased immunological signals 
during the first 20 EDs with FVIII and proposed this therapeutic 
strategy in order to reduce the risk of inhibitor formation in patients 
with severe hemophilia A.63 Given these results, a low- dose prophy-
laxis regimen was tested in a clinical trial, called Early Prophylaxis 
Immunologic Challenge (EPIC) Study (NCT01376700, clinicaltrials.
gov), which had to be terminated prematurely because of an excess 
of inhibitor development.64 Furthermore, the RODIN study demon-
strated that prophylactic FVIII treatment decreased more the inhib-
itor risk in patients with low- risk F8 mutations (small deletions and 
insertions, missense mutations, and splice site mutations) than those 
with high- risk mutations (large gene deletions, nonsense mutations, 
and intron 1 and 22 inversions) (aHR, 0.61, 95% CI, 0.19- 2.0 and 
aHR, 0.85, 95% CI, 0.51- 1.4, respectively).65 In these studies, a low 
inhibitor incidence during prophylaxis was explained as an immune 
tolerance upon exposure to infused FVIII. Cumulatively, the data of 
the literature on the issue of the protective effect of prophylaxis on 
inhibitor formation appear still inconclusive.
The intensity of FVIII treatment covers a spectrum of determi-
nants including peak treatment moments of intense exposure, de-
fined as ≥5 consecutive days with treatment as first exposure or 
anytime in the first 50 EDs. In the multicenter CANAL cohort study, 
peak treatment moments at the time of first treatment was asso-
ciated with a 3.3- fold (95% CI, 2.1- 5.3) higher risk of inhibitor de-
velopment than in patients who received treatment with more days 
elapsing between each treatment.42 In keeping with the CANAL 
study, a multicenter cohort study showed that patients who had 
a major peak treatment moment at the time of the first treatment 
had a 2.1 (95% CI, 1.0- 4.5) times higher risk of inhibitor onset than 
those who only had a treatment on a single day or two consecutive 
days.66 In addition, the effect of peak treatment moments was also 
estimated at any exposure day during the first 50 EDs. Peak treat-
ment moments of three or five consecutive days at any exposure 
day again increased the risk of inhibitor development, but less mark-
edly (RR 1.6; CI, 1.0- 2.6).67 Maclean et al.,62 in a multicenter case- 
control study of the UK Haemophilia Centre Doctors’ Organization 
(UKHCDO), reported that peak treatment moments major than five 
consecutive days at any time during early exposure had the effect to 
increase the inhibitor risk (OR: 2.7, CI, 1.4- 5.4). This finding was con-
firmed in patients with peak treatment moments of 10 EDs or more 
(OR: 5.5, CI, 1.5- 20), whereas peaks of 3 EDs were not associated 
with an increased risk (OR: 0.9, CI, 0.5- 1.8).62
In a systematic review by Eckhardt et al.,67 the findings of 
the three aforementioned studies were pooled. Peak treatment 
F IGURE  1 Environmental risk factors for development of 
inhibitors in severe hemophilia A
Type of FVIII
products
Intensity of treatment
High
influence
Low or
doubtful
influence
Age at first treatment
Surgery Vaccination Infection
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moments at the first treatment were associated with a higher risk 
of inhibitor development. Consecutive treatments on at least 3 days 
was associated with a higher risk of inhibitor development (crude 
OR: 2.1; 95% CI, 1.2- 3.7) compared with <3 EDs. This association 
was more marked when an intensive treatment of 5 EDs was com-
pared with one of <3 EDs (crude OR, 4.1; CI, 2.6- 6.5).67 Recently, 
Calvez et al. confirmed that peak treatment moments greater than 
5 EDs were associated with an increased inhibitor risk (OR: 1.99, CI, 
1.37- 2.91), most pronounced in those patients with peaks of 10 EDs 
or more (OR: 3.51, CI, 2.20- 5.61).46
To sum up, there is agreement between the available studies that 
peak treatment moments are associated with an increased risk of 
inhibitor development and that this effect is stronger when the peak 
treatment occurred at first exposure.
4.2 | Immune system and danger signal
Over the last few years, a commonly suggested explanation for the 
environment- related inhibitor risk is the danger signal effect.9–11 The 
danger theory, which appeared in 1994, proposes that the immune 
system is more worried about damage than foreignness, and is brought 
into action by alarm signals from injured tissues rather than by the 
recognition of nonself.68 The danger model asserts that the immune 
system is activated by danger signals from injured cells, such as those 
exposed to pathogens, toxins, and mechanical damage.69 In hemophilia, 
the danger signal effect implies that endogenous or exogenous danger 
or damage signals present at the time of FVIII infusion stimulate the 
immune response. The danger theory describes how alarm signals from 
stressed, injured, or dying cells may stimulate an immune reaction, with 
no implications of foreign antigens. Therefore, severe bleeds, trauma, 
surgery, or concomitant infections may all be events starting danger 
signaling in hemophilia patients, resulting in an immune reaction to-
wards administered FVIII. It is hypothesized that if the initial meeting 
between FVIII and CD4+T cells occurs in the presence of “danger” 
signals (ie, severe bleeds, trauma, or surgery with major tissue injury) 
the innate immune response becomes activated, with up- regulation 
of a response to FVIII.70 Thus, tissue injury may clarify, partially, the 
increased inhibitor incidence after periods with intensive treatment.
4.3 | Surgery
Surgery is characterized by tissue damage with the related release 
of endogenous danger signals that could potentially promote in-
hibitor development. A case- control study by Santagostino et al. 
in 2005 found no association between surgery and risk of inhibi-
tor development, but the study was too small to lead to definitive 
conclusions.58 In contrast, the CANAL study reported that surgi-
cal procedures carried an increased inhibitor risk42 and a subse-
quent meta- analysis of four studies by Eckhardt et al.67 showed 
that the risk of inhibitor development after surgery at first treat-
ment with FVIII was evidently associated with a heightened risk, 
with a pooled OR of 4.1 (95% CI, 2.0- 8.4) compared with FVIII 
first treatment for other reasons (ie, bleeding or prophylaxis).67 
Nevertheless, the RODIN study showed that surgery at first treat-
ment does not cause an increased inhibitor risk (adjusted RR, 1.2; 
95% CI, 0.54- 2.6). In summary, surgery has been associated in 
some studies with inhibitor formation but heterogeneity in type of 
surgery, and duration and doses of FVIII treatments might justify 
the differences between some of them.
4.4 | Vaccinations
The impact of vaccinations concurrent with FVIII infusion has 
been suggested as a potential exogenous trigger in inhibitor de-
velopment. A recent observational study evaluated data from 375 
PUPs on the effect of vaccinations given close to FVIII exposure 
(48 hours before to 24 hours after), during the first 75 EDs.71 More 
than half of the patients had received a vaccination concomitantly 
with FVIII treatment, but no association was found between in-
hibitor development and vaccinations. Vaccination is a broad term, 
and there may be differences depending on the type of vaccine 
and route of administration. A recent publication by Lai et al.72 
conducted in a hemophilic mouse model suggests that intramus-
cular influenza vaccinations have a protective effect on inhibitor 
formation, whereas intravenous vaccination might have a danger 
signal effect.72 The research on the impact of vaccination on in-
hibitor development is still preliminary, and no definitive conclu-
sions can be drawn.
4.5 | Infections
Few studies have investigated the effect of infections on inhibitor 
development, and thus conclusions are often difficult to draw.
In recent years, there has been substantial progress in the under-
standing of the complexity of the host–microbiota relationship and its 
effects on human health.73,74 Microbiome- wide studies have revealed 
important associations between specific microbiomes and a range 
of ailments including autoimmune disease, cancer, as well as meta-
bolic, neurodegenerative, and inflammatory diseases. Expanding ev-
idence suggests that a dynamic interaction exists between microbes 
and environmental cues (including diet and drugs) within the micro-
bial organ that shapes mucosal and systemic immunity. An interesting 
study, presented at ISTH 2017 meeting by Tarrant et al.,75 reported 
that targeted modification of the gut microbiome in hemophilic mice 
influences inhibitor incidence following administration of recombinant 
FVIII products. Those mice with a manipulated microbiome developed 
anti- FVIII IgG antibodies after a therapeutic regimen with injections of 
FVIII. This study highlights that the gut microbiome may have a cru-
cial role in modulating the immune response to the therapy with FVIII 
products,75 but these data are still preliminary.
5  | CONCLUSION
The most important modifiable risk factor for inhibitor development 
in PUPs is the treatment with a FVIII concentrate. Therefore, the 
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choice of the least immunogenic FVIII product during the first 10 
EDs is crucial.55,56 Furthermore, physicians should plan the least 
intense but effective regimens in PUPs in order to avoid exposure 
to danger signals such as bleeds, trauma, surgery, or concomitant 
infection concurrent with FVIII infusion and perhaps to reduce the 
risk of FVIII inhibitor in PUPs. The impact of multiple environmental 
risk factors is varied and since these factors are often interrelated, 
it is difficult to identify the relative contribution of each single risk 
factor.
6  | FUTURE PERSPECTIVES
The reasons of inhibitor development are still not fully under-
stood and several studies in recent years have revealed the broad 
complexity of this issue. The risk of developing FVIII antibodies is 
strongly related to genetic factors, in particular to nonmodifiable 
F8 gene mutation, as reported by two presentations at the ISTH 
2017 meeting.76,77 One of the most influential and potentially modi-
fiable risk factors is the type of FVIII concentrate, however many 
novel alternative products for hemophilia A treatment are enter-
ing the clinic with exciting results, as reported at the ISTH 2017 
meeting.78–80
The research is currently looking at whether danger signals are 
triggering inhibitor development and also trying to better under-
stand the immunology of inhibitors. Several research studies are ex-
ploring the immune response at the level of the antigen presenting 
cells (APC), T and B cells, and plasma cells and the potential trans-
lational strategies for treating hemophilia patients. New research 
areas are interested in identifying potential early biomarkers which 
might indicate the onset of inhibitors in advance.
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